Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

HPV testing could be used as standard method of cervical screening for women, say Italian scientists

Human papillomavirus (HPV) testing could be used as the standard method of cervical screening for women aged 35 years or older, as it seems to prevent more invasive cases of the disease than cytology screening alone, Italian scientists have said.

20 Jan 2010

Testing for high-risk types of HPV DNA can be effective in preventing invasive cervical cancer

Results from a study of more than 90,000 Italian women published by the Lancet Oncology found that testing for high-risk types of the human papillomavirus (HPV) DNA is significantly more effective in preventing invasive cervical cancer than cytology (Pap testing) alone.

19 Jan 2010

ChromoCure publishes results of cervical cancer study using its Chromosomal Scanner Technology

ChromoCure, Inc. is pleased to announce the publication of the Cervical Cancer Study, PRE-CLINICAL SYSTEM TESTING AND PERFORMANCE ASSESSMENT, conducted in conjunction with a major international Cancer Clinic. The study analyzed samples supplied by the Cancer Clinic with its Proprietary Chromosomal Scanner Technology (full text can be found @ www.ChromoCure.com/library). The study demonstrated not only the correctness of the company's cancer detection approach but also the accuracy of the scan itself. The scanner performed perfectly with flawless detection results.

18 Jan 2010

Study finds large number of new couples among young adults infected with HPV

A groundbreaking study of couples led by Professor Eduardo Franco, Director of McGill University's Cancer Epidemiology Unit, in collaboration with a team of colleagues from McGill and Universit- de Montr-al/Centre Hospitalier de l'Universit- de Montr-al (CHUM), found more than half (56 per cent) of young adults in a new sexual relationship were infected with human papillomavirus (HPV).

18 Jan 2010

Teenage girls are not receiving HPV vaccine, says report

In 2006, the Food and Drug Administration (FDA) approved the Human Papilloma Virus (HPV) vaccine for girls and women ages 9 to 26. As part of Cervical Cancer Awareness Month in January, experts at The University of Texas M. D. Anderson Cancer Center review what we have learned about this controversial vaccine in the past four years.

13 Jan 2010

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by other PD medications.

12 Jan 2010

QIAGEN N.V. announces acquisition of ESE GmbH for $19 million

QIAGEN N.V. today announced that it has acquired ESE GmbH, a privately held developer and manufacturer of UV and fluorescence optical measurement devices. ESE is based in Stockach, Germany. The transaction is valued at up to US$19 million in cash.

From QIAGEN Manchester Limited 12 Jan 2010

Inovio Biomedical expands existing license agreement with the University of Pennsylvania

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that it has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against pandemic influenza, Chikungunya, and foot-and-mouth disease.

11 Jan 2010

WuXi AppTec enters into partnership with QIAGEN

WuXi AppTec Inc. today announced that it has entered into a partnership with QIAGEN to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases.

From QIAGEN Manchester Limited 11 Jan 2010

Time constraints prevent women from attending cervical screening; overcoming practical barriers may maximize screening

While emotional barriers such as embarrassment were thought to be the main reason for not attending, this latest study in the Journal of Medical Screening suggests that practical difficulties may be more important.

8 Jan 2010

Epigenetic diagnosis and therapies, a new strategy for treating cancer

A tumor's genetic profile is often useful when diagnosing and deciding on treatment for certain cancers, but inexplicably, genetically similar leukemias in different patients do not always respond well to the same therapy.

7 Jan 2010

UAB issues updated guidelines for childhood and teen immunization schedule

The co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases is a member of the committee that this week issued updated guidelines for childhood and teen immunizations to include formal recommendations that children older than 6 months get the H1N1 influenza vaccine to guard against swine flu, and that combination vaccines are generally preferred over separate injections.

7 Jan 2010

Authors explain why health care reform initiative should include CER

The current health care reform bills approved by the House and the Senate seek to expand health insurance coverage while containing costs; however, the proposed policy changes are not guaranteed to improve health for individuals or society, according to a "Perspective" article by faculty of Weill Cornell Medical College in the Jan. 6 New England Journal of Medicine.

7 Jan 2010

Weill Cornell Medical College offers innovative program to teach medical students about health care system

While medical students are required to know the names of every body part and disease, most graduate with only a cursory understanding of how the health care system actually works, and some of the ways it doesn't.

6 Jan 2010

Wisconsin rural hospitals hope for federal money to offset state Medicaid cut

Wisconsin's rural hospitals hope to offset a state Medicaid cut with a tax that would bring more federal money to the hospitals. The proposed tax on the state's 59 'critical access' hospitals, all in rural areas, would prevent the hospitals from closing important services, officials say.

5 Jan 2010

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

Johns Hopkins University researchers have created biodegradable nanosized particles that can easily slip through the body's sticky and viscous mucus secretions to deliver a sustained-release medication cargo.

5 Jan 2010

EPO approves Advaxis patent application for Listeria Antigens

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received notification from the European Patent Office (EPO) that Advaxis patent application 98957980.0 titled “Bacterial Vaccines Comprising Auxotrophic, Attenuated Strains of Listeria Expressing Heterologous Antigens,” has been granted and will be issued as patent #1032417

4 Jan 2010

U.S. Congress designates January as ‘Cervical Health Awareness Month’

Nearly 4,000 women in America will die this year from cervical cancer. These cancers are, largely, preventable, and raising public awareness can save lives. It's why the U.S. Congress has designated January as Cervical Health Awareness Month.

31 Dec 2009

Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.

29 Dec 2009

Cervical cancer more common among poorer women than more affluent women, say scientists

One of the reasons why cervical cancer is more common among poorer women could be because they start having sex at a younger age than more affluent women, scientists have said.

23 Dec 2009

Cervical Cancer News and Research

Further Reading

HPV testing could be used as standard method of cervical screening for women, say Italian scientists

Testing for high-risk types of HPV DNA can be effective in preventing invasive cervical cancer

ChromoCure publishes results of cervical cancer study using its Chromosomal Scanner Technology

Study finds large number of new couples among young adults infected with HPV

Teenage girls are not receiving HPV vaccine, says report

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

QIAGEN N.V. announces acquisition of ESE GmbH for $19 million

Inovio Biomedical expands existing license agreement with the University of Pennsylvania

WuXi AppTec enters into partnership with QIAGEN

Time constraints prevent women from attending cervical screening; overcoming practical barriers may maximize screening

Epigenetic diagnosis and therapies, a new strategy for treating cancer

UAB issues updated guidelines for childhood and teen immunization schedule

Authors explain why health care reform initiative should include CER

Weill Cornell Medical College offers innovative program to teach medical students about health care system

Wisconsin rural hospitals hope for federal money to offset state Medicaid cut

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

EPO approves Advaxis patent application for Listeria Antigens

U.S. Congress designates January as ‘Cervical Health Awareness Month’

Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer

Cervical cancer more common among poorer women than more affluent women, say scientists

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News